Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MAIA
MAIA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MAIA News
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
Feb 05 2026
Newsfilter
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
Jan 28 2026
Newsfilter
MAIA Biotechnology 2025 Highlights: Ateganosine Clinical Progress and Funding Support
Jan 21 2026
NASDAQ.COM
MAIA Biotechnology Secures FDA Fast Track for Ateganosine, Targeting Early Approval in 18 Months
Jan 20 2026
Newsfilter
Amylyx and MAIA Executives Increase Stock Holdings Amid Market Fluctuations
Dec 26 2025
NASDAQ.COM
MAIA Biotechnology Directors Purchase 179,737 Shares, Raising $1.51 Million
Dec 24 2025
Globenewswire
MAIA Biotechnology Raises $1.51M by Selling 1.23M Shares at $1.224 Each
Dec 16 2025
Newsfilter
MAIA Biotechnology Raises $1.51 Million by Selling 1.23 Million Shares at $1.224 Each
Dec 16 2025
Globenewswire
MAIA Biotechnology Initiates Phase 3 Trial for ATEG in NSCLC
Dec 11 2025
Globenewswire
MAIA Biotechnology Initiates Phase 3 Trial for ATEG in NSCLC
Dec 11 2025
Newsfilter
MAIA Biotechnology Launches New Lung Cancer Therapy with $34.1 Billion Market Potential
Dec 10 2025
Globenewswire
MAIA Biotechnology Unveils New Lung Cancer Therapy with $34.1 Billion Market Potential
Dec 10 2025
Newsfilter
MAIA Biotechnology Executives Purchase 182,445 Shares, Signaling Confidence
Dec 01 2025
Globenewswire
Diamond Equity Research Publishes Update on MAIA Biotechnology, Inc. (NYSE: MAIA)
Nov 10 2025
Newsfilter
MAIA Biotechnology Showcases Ongoing Trial Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Treatments
Oct 27 2025
Newsfilter
MAIA Biotechnology Reports 30-Month Patient Survival Data from Ongoing Phase 2 Trial for Non-Small Cell Lung Cancer
Oct 23 2025
Newsfilter
Show More News
